Overview

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

This is a randomized controlled study to evaluate the efficacy and safety of toripalimab plus capecitabine as postoperative adjuvant therapy for patients with resectable advanced extrahepatic biliary tract cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

Capecitabine
toripalimab